<DOC>
	<DOCNO>NCT00718770</DOCNO>
	<brief_summary>This study plan learn drug call bexarotene treatment advance thyroid cancer . Subjects ask study thyroid cancer respond radioactive iodine therapy show sign aggressive behavior . Bexarotene FDA approve treatment type skin cancer call cutaneous T-cell lymphoma , FDA approve use . Bexarotene investigational treatment thyroid cancer . The purpose research study test well study drug work human . The study doctor want know : 1 . The subject thyroid cancer get small take study drug . 2 . The subject thyroid cancer take radioactive iodine well treatment study drug treatment .</brief_summary>
	<brief_title>A Pilot Clinical Trial Poorly Differentiated Thyroid Cancer - Correlation Retinoid Peroxisome-proliferator-activated Receptor ( PPARy ) Expression</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Bexarotene</mesh_term>
	<criteria>Subject must histologically/cytologically confirm diagnosis papillary , follicular , anaplastic thyroid cancer ( follicular cell derive thyroid cancer ) . Subjects must evidence follicular cellderived thyroid cancer progression . In patient anatomically stable disease , PET positive lesion also eligible give poor prognostic risk PET positive thyroid cancer . Subjects must eligible surgical resection . Subjects must measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) criterion . Subjects must laboratory value fall within certain range . Subjects must age 18 year old . Subjects must provide write informed consent prior study procedure perform . Females childbearing potential must negative pregnancy test prior enrollment . All eligible subject must willing use adequate contraception throughout duration study . Subjects must willing submit primary tumor tissue sample immunohistochemical analysis . Subjects option provide one additional test tube blood take baseline , 6 month 1 year banking plasma potential future study ( genetic testing conduct ) . The current planned analysis assessment potential peripheral marker rexinoid responsive cancer leukemia inhibitory factor ( LIF ) Subjects known history hyperlipidemia refractory treatment . Subjects know history hypertriglyceridemia refractory treatment . Subjects leukopenia reference range University Colorado Hospital ( UCH ) laboratory . Subjects , pregnant , desire become pregnant breastfeeding . Subjects unwilling unable comply study medication administration , study guideline , determine investigator . Subjects prior history malignancy exception adequately treat basal cell skin cancer , situ cervical cancer cancer subject disease free 3 year . Subjects without radiographically assessable disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Not respond</keyword>
	<keyword>Radioactive iodine</keyword>
	<keyword>Therapy</keyword>
	<keyword>Shows sign</keyword>
	<keyword>Aggressive behavior</keyword>
</DOC>